AIVimmunity

Finland faced an unexpectedly large highly pathogenic avian influenza A(H5N1) epidemic in wild birds that spread to several dozen fur farms in 2023. Due to the exceptional epidemic situation and the increased risk of a pandemic, Finland has decided to offer an avian influenza vaccine to people who are at risk of being exposed to avian influenza in 2024 when the vaccine becomes available. In this research consortium, AIVimmunity, we will measure antibody- and cell-mediated immune responses induced by seasonal and avian influenza vaccines and evaluate the strength, specificity, persistence, and cross-protection of these immune responses against different A(H5N1) avian influenza virus strains. Through this research consortium we will produce critical up-to-date information for not only the control of the national avian influenza epidemic, but moreover for preparedness for a potential global pandemic.

2024

2028